Hit enter to search or ESC to close

Investor Centre

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various forms of Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical to intercede in disease processes. Alterity is located in Melbourne, Australia and San Francisco, California, USA. The Company is listed on the Australian Securities Exchange (ASX: ATH) and NASDAQ (NASDAQ: ATHE).

Investment Highlights

  • Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
  • ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
  • ATH434 has completed its Phase 1 clinical trial program.
  • First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
  • FDA Orphan Drug designation in the U.S. and EU for ATH434 for the treatment of MSA received.
  • Significant market potential in MSA – estimated peak sales of US$725M.

Warning: getimagesize(https://alteritytherapeutics.com/wp-content/uploads/Appendix 4C – Q2 FY22 Quarterly Cash Flow Report - 27 January 2022): failed to open stream: HTTP request failed! HTTP/1.1 400 Bad Request in /var/www/wp-content/plugins/document-gallery/inc/thumbers/class-abstract-thumber.php on line 135

Investor Resources

Corporate presentations


Warning: getimagesize(https://alteritytherapeutics.com/wp-content/uploads/Investor Presentation November 2022): failed to open stream: HTTP request failed! HTTP/1.1 400 Bad Request in /var/www/wp-content/plugins/document-gallery/inc/thumbers/class-abstract-thumber.php on line 135

Analyst Reports

ASX Announcements

2022

2021

2020

2019

2018

Financial reports

2021

2020

2019

2018

Corporate governance

News

Receive news from Alterity Therapeutics